Prothena Corp PLC (NAS:PRTA)
$ 21.04 -0.09 (-0.43%) Market Cap: 1.13 Bil Enterprise Value: 602.18 Mil PE Ratio: 0 PB Ratio: 2.25 GF Score: 64/100

Prothena Corporation PLC to Discuss AFFIRM-AL Study - Conference Call Transcript

Feb 02, 2021 / 01:00PM GMT
Release Date Price: $14.35 (+30.45%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to Prothena's AFFIRM-AL study conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Ellen Rose, Prothena's Head of Communications. Please go ahead, ma'am.

Ellen Rose
Prothena Corporation plc - Head of Communications

Thank you, operator. Hello, everyone, and welcome to Prothena's investor conference call to review the announcement regarding birtamimab and the confirmatory Phase III AFFIRM-AL study in Mayo Stage IV patients with AL amyloidosis. Please review the press release we issued on Monday afternoon, which is available on our website at prothena.com.

On today's call, Dr. Gene Kinney, our President and Chief Executive Officer, will provide introductory remarks about birtamimab and the series of activities that has led to initiating the AFFIRM-AL study. Dr. Wagner Zago, our Chief Scientific Officer, will speak about the underlying

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot